{"id":"W3028956426","doi":"10.1200/jco.2020.38.15_suppl.5063","title":"Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Sunnybrook Hospital; Foothills Medical Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Dalhousie University; University Health Network; Queen's University; Baker Hughes (Canada); University of Calgary","funders":"","keywords":"Medicine; Nivolumab; Axitinib; Ipilimumab; Renal cell carcinoma; Pazopanib; Sunitinib; Internal medicine; Everolimus; Oncology; Pembrolizumab; Clinical endpoint; Discontinuation; Cancer; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004696192,0.0003273754,0.0007968438,0.002529805,0.0004135575,0.001787585,0.0008296588,0.0004195283,0.0009615629],"category_scores_gemma":[0.01013466,0.0001175354,0.0006613607,0.003136265,0.0002944915,0.0009514926,0.001696953,0.0005788391,0.0003458002],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002066528,"about_ca_system_score_gemma":0.001627228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006338681,"about_ca_topic_score_gemma":0.01057768,"domain_scores_codex":[0.9967176,0.0007998652,0.0006648507,0.0004968091,0.001038145,0.0002826852],"domain_scores_gemma":[0.9856047,0.00127837,0.009762735,0.0006171041,0.00181699,0.0009199869],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002911814,0.00003846824,0.9816319,0.00008673822,0.000109902,0.00003263403,0.00005590566,0.0004590297,0.0001754854,0.0001338315,0.002011531,0.01497339],"study_design_scores_gemma":[0.00006419789,0.0003720143,0.9867718,0.0001368582,0.000151796,0.0007350614,0.0001684339,0.003698534,0.0008933713,0.0001962046,0.006789349,0.00002230013],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9523368,0.009525601,0.003402802,0.00111365,0.00006893031,0.0003980924,0.02336716,0.0001099644,0.009677024],"genre_scores_gemma":[0.9835452,0.0005973828,0.002360282,0.000163875,0.00005597021,0.0001381679,0.01282386,0.00001552839,0.0002997134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006338681,"threshold_uncertainty_score":0.02483612,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1436503280228691,"score_gpt":0.4643076875995076,"score_spread":0.3206573595766385,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}